Home Cart Sign in  
Chemical Structure| 1429881-91-3 Chemical Structure| 1429881-91-3

Structure of UNC2025
CAS No.: 1429881-91-3

Chemical Structure| 1429881-91-3

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

UNC2025 is an inhibitor of Mer and Flt3 with IC50 of 0.8 nM and 0.74 nM, respectively.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of UNC2025

CAS No. :1429881-91-3
Formula : C28H40N6O
M.W : 476.66
SMILES Code : O[C@H]1CC[C@H](N2C=C(C3=CC=C(CN4CCN(C)CC4)C=C3)C5=CN=C(NCCCC)N=C52)CC1
MDL No. :MFCD28142874
InChI Key :MJSHVHLADKXCML-UHFFFAOYSA-N
Pubchem ID :73425588

Safety of UNC2025

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of UNC2025

RTK

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
TRP 231.6 nM 5 days Evaluate the inhibitory effect of UNC2025 on TRP cell growth, with an IC50 of 231.6 nM. PMC5761530
EWS894 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
MHH-ES-1 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
Kasumi-1 AML cells 200-300nM 48 hours Induced cell death, 25-90% of cells died after 48-hour treatment PMC5354980
CHLA-32 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
GSC20 1.5 µM 5 days Evaluate the inhibitory effect of UNC2025 on GSC20 cell growth, with an IC50 of 1.5 µM. PMC5761530
GSC11 86 nM 5 days Evaluate the inhibitory effect of UNC2025 on GSC11 cell growth, with an IC50 of 86 nM. PMC5761530
SK-N-MC cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
CHLA-10 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
TC-71 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
A673 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
AML-123009 patient sample 25-300nM 48 hours Inhibited colony formation, >90% inhibition at 300nM PMC5354980
Jurkat T-ALL cells 200-300nM 48 hours Induced cell death, 25-90% of cells died after 48-hour treatment PMC5354980
697 B-ALL cells 200-300nM 48 hours Induced cell death, 25-90% of cells died after 48-hour treatment PMC5354980
M2 macrophages 1 µg/mL 2 hours Inhibit MerTK phosphorylation and block efferocytosis of apoptotic cells PMC10039929
EOC 2 199 nM 5 days Evaluate the inhibitory effect of UNC2025 on EOC 2 cell growth, with an IC50 of 199 nM. PMC5761530
J774 134 nM 5 days Evaluate the inhibitory effect of UNC2025 on J774 cell growth, with an IC50 of 134 nM. PMC5761530
TC-32 cells 1 μM 24 hours UNC2025 suppressed SN-38-induced Akt and ERK signaling activation PMC11192891
NOMO-1 AML cells 200-300nM 48 hours Induced cell death, 25-90% of cells died after 48-hour treatment PMC5354980
697 B-ALL cells 0.01, 0.1, 1.0, 10, 100, 1000 nM 10 minutes Induced cell death, 25-90% of cells died after 48-hour treatment PMC4148167
Bone marrow-derived dendritic cells (BMDCs) 10 µg/mL 12 hours To evaluate the effect of Loratadine on dendritic cell antigen-presenting function, results showed that Loratadine significantly reduced the production of IL-4, IL-13, and IL-17A PMC10039929
B16F10 melanoma cells 5 µM 6 hours Cell apoptosis was assessed by FITC-Annexin V and TUNEL staining. Clofazimine induced apoptosis. PMC10039929
Schwannoma cells 0.03-6.0 μM 72 hours and 7 days UNC2025 decreased the total number of schwannoma cells, increased the number of dead cells, and reduced the proliferation of Ki67-positive cells. PMC11458476
Meningioma cells 0.03-6.0 μM 72 hours and 7 days UNC2025 decreased the total number of meningioma cells, increased the number of dead cells, and reduced the proliferation of Ki67-positive cells. PMC11458476
Murine washed platelets 0.5 µM 15 minutes Inhibited collagen-stimulated platelet aggregation PMC5858881
Human platelet rich plasma (PRP) 5 µM 15 minutes Inhibited collagen-stimulated platelet aggregation PMC5858881
Human washed platelets (WP) 0.5 µM 15 minutes Inhibited collagen-stimulated platelet aggregation PMC5858881
Meningioma cells 1 µM 72 hours UNC2025 decreased the total number of meningioma cells, increased the number of dead cells, and reduced the proliferation of Ki67-positive cells. PMC10725030
MeWo 100 nM 72 hours Reduction in survivin levels PMC9787186
A101D 50 nM 10 days Reduction in colony formation PMC9787186
G361 1000 nM 90 minutes Inhibition of MERTK activation and downstream signaling PMC9787186
HMCB 300 nM 90 minutes Inhibition of MERTK activation and downstream signaling PMC9787186
H1299 300 nM 72 hours PMC4704683
Colo699 300 nM 72 hours To assess the effect of UNC2025 on apoptosis, results showed UNC2025 significantly increased apoptosis. PMC4704683
A549 300 nM 72 hours Evaluate cytotoxicity, showing low cytotoxicity PMC4704683
H2228 300 nM 72 hours To assess the effect of UNC2025 on apoptosis, results showed UNC2025 significantly increased apoptosis. PMC4704683

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice TRP allograft model Oral gavage 65 mg/kg Once daily starting from day 7 Evaluate the effect of UNC2025 alone or in combination with radiotherapy on the survival of TRP allograft model mice. Results showed that UNC2025 alone did not significantly prolong survival, but when combined with radiotherapy, 19.4% of mice survived more than 60 days, with complete tumor regression in some mice. PMC5761530
Nude mice MHH-ES-1 xenograft model Intraperitoneal injection 10 mg/kg Every 3 days for 28 days UNC2025 enhanced irinotecan's suppression of tumor growth PMC11192891
NSG mice 697 B-ALL xenograft model Oral 50-75mg/kg Once daily, continuous treatment Significantly reduced tumor burden, median survival increased from 26 days to 70 days PMC5354980
NOD/SCID/gamma mice Human leukemia xenograft model Oral 3 mg/kg Single dose, bone marrow cells collected 30 minutes later To evaluate the inhibitory effect of UNC2025 on Mer phosphorylation in vivo, results showed significant reduction in Mer phospho-protein levels PMC4148167
C57BL/6 mice B16F10 melanoma model Peritumoral injection 2.7 µg UNC2025/mouse Every 3 days for two times Inhibit tumor growth and metastasis, enhance antitumor immune responses PMC10039929
Mice FeCl3-Induced Carotid Artery Thrombosis model Intravenous injection 3 mg/kg Single dose, circulated for 30 minutes Prolonged time to initial clot formation and decreased thrombus stability PMC5858881
Male C57BL/6 mice Hepatic ischemia-reperfusion injury model Intravenous injection 50 mg/kg Single dose, followed by reperfusion for up to 6 or 24 hours UNC2025 significantly inhibited MSC-EVs-induced phagocytosis of apoptotic cells by macrophages and increased liver injury PMC11387478
Nude mice BRAF-mutated patient-derived xenograft model Oral gavage 50 mg/kg Twice daily for 50 days Significantly reduced tumor growth PMC9787186
Nude mice Subcutaneous xenograft model Oral gavage 30 mg/kg or 50 mg/kg Twice daily for several weeks To assess the effect of UNC2025 on tumor growth, results showed UNC2025 significantly inhibited tumor growth. PMC4704683

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.10mL

0.42mL

0.21mL

10.49mL

2.10mL

1.05mL

20.98mL

4.20mL

2.10mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories